Open AccessABCB1 polymorphism and acenocoumarol safety in patients with valvular atrial fibrillation
Author(s) -
А. В. Рожков,
Д. А. Сычев,
Р. Е. Казаков
Publication year - 2015
Publication title -
international journal of risk and safety in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.306
H-Index - 22
eISSN - 1878-6847
pISSN - 0924-6479
DOI - 10.3233/jrs-150672
Subject(s) - acenocoumarol , atrial fibrillation , cyp2c9 , genotype , medicine , pharmacodynamics , pharmacogenetics , gastroenterology , vitamin k antagonist , warfarin , genotyping , pharmacology , blood sampling , pharmacokinetics , biology , genetics , gene , cytochrome p450 , metabolism
Oral anticoagulant drugs (AD) are commonly used to treat patients with thromboembolic diseases. The ADs have narrow therapeutic index and wide pharmacokinetic and pharmacodynamic interindividual variability. Some genetic variations could influence interindividual variability in response to AD. Acenocoumarol (AC) is a coumarin, vitamin K derivate with antagonistic activity, used as anticoagulant therapy mainly in Central Europe and Latin America. P - glycoprotein (PGP), a transporter encoded by the ABCB1 gene, plays a major role in the drug disposition [1]. PGP is expressed in normal tissues, where it performs a defensive role against potentially toxic substances in intestinal cells and endothelial cells of the brain capillary endothelium. ABCB1 - is highly polymorphic, C3435T polymorphism in exon 26 has been associated with the expression of PGP [2]. There is some evidence that PGP could influence coumarin sensitivity.